The goal is not flexibility improvement
Wong, PhD, MPH, a professor of medicine at the University of California, Irvine School of Medicine, and colleagues noted that the impact glucagon-like peptide 1 (GLP-1) receptor agonists have on weight loss have recently generated interest and investigation. Semaglutide activates GLP-1 receptors, improving incretin function and insulin secretion (glucose-dependent), inhibiting glucagon release and suppressing hepatic gluconeogenesis, resulting in reductions in both fasting as well as postprandial glucose, they wrote in Cardiovascular Drugs and Therapy
These dual agonists are newer but gaining traction quickly due to their reported weight loss efficacy
Clinical data show that within 24 weeks, over 75% improved mood and sleep, by 46 weeks about 70% had better memory and less brain fog, and over 70% of women found relief from menopause symptoms
95% CI, 1.05-1.74) also had a higher risk for thyroid cancer than non-users
Cht ny ging nh mt nam chm ht cc gc t do, kim loi nng v c t hp th qua da, hi th, nc ung, thc n v kch hot o thi ra khi c th c th chng ta khe mnh hn
